#begin document (nw/wsj/15/wsj_1542); part 000
nw/wsj/15/wsj_1542   0    0               The     DT             (TOP(S(NP*         -    -   -   -   (ORG*   (ARG0*        *        *           *       (4
nw/wsj/15/wsj_1542   0    1              Food    NNP                  (NML*         -    -   -   -       *        *        *        *           *        -
nw/wsj/15/wsj_1542   0    2               and     CC                      *         -    -   -   -       *        *        *        *           *        -
nw/wsj/15/wsj_1542   0    3              Drug    NNP                      *)        -    -   -   -       *        *        *        *           *        -
nw/wsj/15/wsj_1542   0    4    Administration    NNP                      *)        -    -   -   -       *)       *)       *        *           *        4)
nw/wsj/15/wsj_1542   0    5              said    VBD                   (VP*        say  01   1   -       *      (V*)       *        *           *        -
nw/wsj/15/wsj_1542   0    6          American    NNP            (SBAR(S(NP*         -    -   -   -   (ORG*   (ARG1*   (ARG0*   (ARG0*           *       (0
nw/wsj/15/wsj_1542   0    7              Home    NNP                      *         -    -   -   -       *        *        *        *           *        -
nw/wsj/15/wsj_1542   0    8          Products    NNP                      *         -    -   -   -       *        *        *        *           *        -
nw/wsj/15/wsj_1542   0    9             Corp.    NNP                      *)        -    -   -   -       *)       *        *)       *)          *        0)
nw/wsj/15/wsj_1542   0   10            agreed    VBD                   (VP*      agree  01   3   -       *        *      (V*)       *           *        -
nw/wsj/15/wsj_1542   0   11                to     TO                 (S(VP*         -    -   -   -       *        *   (ARG1*        *           *        -
nw/wsj/15/wsj_1542   0   12            recall     VB                   (VP*     recall  01   2   -       *        *        *      (V*)          *        -
nw/wsj/15/wsj_1542   0   13           certain     JJ                (NP(NP*         -    -   -   -       *        *        *   (ARG1*      (ARG1*       (5
nw/wsj/15/wsj_1542   0   14           generic     JJ                      *         -    -   -   -       *        *        *        *           *        -
nw/wsj/15/wsj_1542   0   15             drugs    NNS                      *)      drug   -   1   -       *        *        *        *           *)       -
nw/wsj/15/wsj_1542   0   16              that    WDT            (SBAR(WHNP*)        -    -   -   -       *        *        *        *    (R-ARG1*)       -
nw/wsj/15/wsj_1542   0   17              were    VBD                 (S(VP*         -    -   -   -       *        *        *        *           *        -
nw/wsj/15/wsj_1542   0   18          produced    VBN                   (VP*    produce  01   1   -       *        *        *        *         (V*)       -
nw/wsj/15/wsj_1542   0   19                by     IN                   (PP*         -    -   -   -       *        *        *        *      (ARG0*        -
nw/wsj/15/wsj_1542   0   20               its   PRP$                (NP(NP*         -    -   -   -       *        *        *        *           *    (6|(0)
nw/wsj/15/wsj_1542   0   21           Quantum    NNP                  (NML*         -    -   -   -   (ORG*        *        *        *           *        -
nw/wsj/15/wsj_1542   0   22          Pharmics    NNP                      *)        -    -   -   -       *)       *        *        *           *        -
nw/wsj/15/wsj_1542   0   23              unit     NN                      *)      unit   -   2   -       *        *        *        *           *        -
nw/wsj/15/wsj_1542   0   24                in     IN                   (PP*         -    -   -   -       *        *        *        *           *        -
nw/wsj/15/wsj_1542   0   25        Amityville    NNP                (NP(NP*)        -    -   -   -    (GPE)       *        *        *           *        -
nw/wsj/15/wsj_1542   0   26                 ,      ,                      *         -    -   -   -       *        *        *        *           *        -
nw/wsj/15/wsj_1542   0   27               N.Y    NNP   (NP*)))))))))))))))))        -    -   -   -    (GPE)       *)       *)       *)          *)    6)|5)
nw/wsj/15/wsj_1542   0   28                 .      .                     *))        -    -   -   -       *        *        *        *           *        -

nw/wsj/15/wsj_1542   0    0          Quantum   NNP      (TOP(S(NP*)              -    -   -   -     (ORG)   (ARG0*)      (ARG0*)       *            *        *         *    (6)
nw/wsj/15/wsj_1542   0    1          stopped   VBD            (VP*             stop  01   1   -        *       (V*)           *        *            *        *         *     -
nw/wsj/15/wsj_1542   0    2         shipping   VBG            (VP*             ship  01   1   -        *    (ARG1*          (V*)       *            *        *         *     -
nw/wsj/15/wsj_1542   0    3              the    DT            (NP*               -    -   -   -        *         *       (ARG1*        *            *        *         *    (5
nw/wsj/15/wsj_1542   0    4            drugs   NNS               *)            drug   -   1   -        *         *            *)       *            *        *         *     5)
nw/wsj/15/wsj_1542   0    5             last    JJ            (NP*               -    -   -   -   (DATE*         *   (ARGM-TMP*        *            *        *         *    (1
nw/wsj/15/wsj_1542   0    6            month    NN               *)           month   -   2   -        *)        *            *)       *            *        *         *     1)
nw/wsj/15/wsj_1542   0    7                ,     ,               *               -    -   -   -        *         *            *        *            *        *         *     -
nw/wsj/15/wsj_1542   0    8        following   VBG            (PP*           follow  01   2   -        *         *   (ARGM-TMP*      (V*)           *        *         *     -
nw/wsj/15/wsj_1542   0    9                a    DT         (NP(NP*               -    -   -   -        *         *            *   (ARG2*            *        *         *     -
nw/wsj/15/wsj_1542   0   10          federal    JJ               *               -    -   -   -        *         *            *        *            *        *         *     -
nw/wsj/15/wsj_1542   0   11    investigation    NN               *)   investigation   -   1   -        *         *            *        *            *        *         *     -
nw/wsj/15/wsj_1542   0   12        regarding   VBG            (VP*           regard   -   3   -        *         *            *        *            *        *         *     -
nw/wsj/15/wsj_1542   0   13      information    NN         (NP(NP*)     information   -   1   -        *         *            *        *       (ARG1*)       *         *     -
nw/wsj/15/wsj_1542   0   14              the    DT     (SBAR(S(NP*               -    -   -   -        *         *            *        *       (ARG0*   (ARG0*         *    (6
nw/wsj/15/wsj_1542   0   15          company    NN               *)         company   -   1   -        *         *            *        *            *)       *)        *     6)
nw/wsj/15/wsj_1542   0   16         supplied   VBD            (VP*           supply  01   1   -        *         *            *        *          (V*)       *         *     -
nw/wsj/15/wsj_1542   0   17               to    TO          (S(VP*               -    -   -   -        *         *            *        *   (ARGM-PNC*        *         *     -
nw/wsj/15/wsj_1542   0   18           obtain    VB            (VP*           obtain  01   1   -        *         *            *        *            *      (V*)        *     -
nw/wsj/15/wsj_1542   0   19            three    CD            (NP*               -    -   -   -        *         *            *        *            *   (ARG1*         *     -
nw/wsj/15/wsj_1542   0   20             drug    NN               *             drug   -   1   -        *         *            *        *            *        *    (ARG1*)    -
nw/wsj/15/wsj_1542   0   21        approvals   NNS   *)))))))))))))        approval  01   1   -        *         *)           *)       *)           *)       *)      (V*)    -
nw/wsj/15/wsj_1542   0   22                .     .              *))              -    -   -   -        *         *            *        *            *        *         *     -

nw/wsj/15/wsj_1542   0    0               The    DT      (TOP(S(NP*              -    -   -   -       *       (ARG0*        *         *            *        *      *            *             *      (4
nw/wsj/15/wsj_1542   0    1               FDA   NNP               *)             -    -   -   -    (ORG)           *)       *         *            *        *      *            *             *       4)
nw/wsj/15/wsj_1542   0    2         requested   VBD            (VP*         request  01   1   -       *          (V*)       *         *            *        *      *            *             *       -
nw/wsj/15/wsj_1542   0    3               the    DT         (NP(NP*              -    -   -   -       *       (ARG1*        *         *            *        *      *            *             *       -
nw/wsj/15/wsj_1542   0    4            recall    NN               *)         recall  01   1   -       *            *      (V*)        *            *        *      *            *             *       -
nw/wsj/15/wsj_1542   0    5                of    IN            (PP*              -    -   -   -       *            *   (ARG1*         *            *        *      *            *             *       -
nw/wsj/15/wsj_1542   0    6           Quantum   NNP         (NP(NP*              -    -   -   -    (ORG)           *        *         *            *        *      *            *             *   (5|(6
nw/wsj/15/wsj_1542   0    7                's   POS               *)             -    -   -   -       *            *        *         *            *        *      *            *             *       6)
nw/wsj/15/wsj_1542   0    8          mioxidil    NN       (NML(NML*              -    -   -   -       *            *        *         *            *        *      *            *             *       -
nw/wsj/15/wsj_1542   0    9           tablets   NNS               *              -    -   -   -       *            *        *         *            *        *      *            *             *       -
nw/wsj/15/wsj_1542   0   10                 ,     ,               *)             -    -   -   -       *            *        *         *            *        *      *            *             *       -
nw/wsj/15/wsj_1542   0   11      chlorazepate    NN       (NML(NML*              -    -   -   -       *            *        *         *            *        *      *            *             *       -
nw/wsj/15/wsj_1542   0   12       dipotassium    NN               *)             -    -   -   -       *            *        *         *            *        *      *            *             *       -
nw/wsj/15/wsj_1542   0   13           tablets   NNS               *)             -    -   -   -       *            *        *         *            *        *      *            *             *       -
nw/wsj/15/wsj_1542   0   14               and    CC               *              -    -   -   -       *            *        *         *            *        *      *            *             *       -
nw/wsj/15/wsj_1542   0   15     meclofenamate    NN       (NML(NML*              -    -   -   -       *            *        *         *            *        *      *            *             *       -
nw/wsj/15/wsj_1542   0   16            sodium    NN               *)             -    -   -   -       *            *        *         *            *        *      *            *             *       -
nw/wsj/15/wsj_1542   0   17          capsules   NNS           *)))))             -    -   -   -       *            *)       *)        *            *        *      *            *             *       5)
nw/wsj/15/wsj_1542   0   18           because    IN          (SBAR*              -    -   -   -       *   (ARGM-CAU*        *         *            *        *      *            *             *       -
nw/wsj/15/wsj_1542   0   19                 ,     ,           (PRN*              -    -   -   -       *            *        *         *            *        *      *            *             *       -
nw/wsj/15/wsj_1542   0   20                it   PRP          (S(NP*)             -    -   -   -       *            *        *    (ARG0*)           *        *      *            *             *      (4)
nw/wsj/15/wsj_1542   0   21              said   VBD           (VP*))            say  01   1   -       *            *        *       (V*)           *        *      *            *             *       -
nw/wsj/15/wsj_1542   0   22                 ,     ,               *)             -    -   -   -       *            *        *         *            *        *      *            *             *       -
nw/wsj/15/wsj_1542   0   23               the    DT       (S(NP(NP*              -    -   -   -       *            *        *         *            *        *      *       (ARG1*             *      (2
nw/wsj/15/wsj_1542   0   24              size    NN               *)           size   -   1   -       *            *        *         *            *        *      *            *             *       -
nw/wsj/15/wsj_1542   0   25                of    IN            (PP*              -    -   -   -       *            *        *         *            *        *      *            *             *       -
nw/wsj/15/wsj_1542   0   26               the    DT         (NP(NP*              -    -   -   -       *            *        *         *       (ARG1*   (ARG0*      *            *             *       -
nw/wsj/15/wsj_1542   0   27        production    NN               *      production   -   1   -       *            *        *         *            *        *      *            *             *       -
nw/wsj/15/wsj_1542   0   28              runs   NNS               *)             -    -   -   -       *            *        *         *            *)       *)     *            *             *       -
nw/wsj/15/wsj_1542   0   29         submitted   VBN            (VP*          submit  01   2   -       *            *        *         *          (V*)       *      *            *             *       -
nw/wsj/15/wsj_1542   0   30               for    IN            (PP*              -    -   -   -       *            *        *         *       (ARG3*        *      *            *             *       -
nw/wsj/15/wsj_1542   0   31           testing    NN           (NP*))           test   -   4   -       *            *        *         *            *)       *      *            *             *       -
nw/wsj/15/wsj_1542   0   32                to    TO          (S(VP*              -    -   -   -       *            *        *         *   (ARGM-PNC*        *      *            *             *       -
nw/wsj/15/wsj_1542   0   33              gain    VB            (VP*            gain  02   1   -       *            *        *         *            *      (V*)     *            *             *       -
nw/wsj/15/wsj_1542   0   34               FDA   NNP            (NP*              -    -   -   -    (ORG)           *        *         *            *   (ARG1*      *            *             *      (4)
nw/wsj/15/wsj_1542   0   35          approval    NN        *))))))))             -    -   -   -       *            *        *         *            *)       *)     *            *)            *       2)
nw/wsj/15/wsj_1542   0   36               was   VBD            (VP*              be  03   1   -       *            *        *         *            *        *    (V*)           *             *       -
nw/wsj/15/wsj_1542   0   37                in    IN            (PP*              -    -   -   -       *            *        *         *            *        *      *   (ARGM-LOC*             *       -
nw/wsj/15/wsj_1542   0   38              each    DT            (NP*              -    -   -   -       *            *        *         *            *        *      *            *             *       -
nw/wsj/15/wsj_1542   0   39              case    NN              *))           case   -   1   -       *            *        *         *            *        *      *            *)            *       -
nw/wsj/15/wsj_1542   0   40    misrepresented   VBD            (VP*    misrepresent  01   2   -       *            *        *         *            *        *      *          (V*)            *       -
nw/wsj/15/wsj_1542   0   41                as    IN            (PP*              -    -   -   -       *            *        *         *            *        *      *       (ARG2*             *       -
nw/wsj/15/wsj_1542   0   42              much    RB     (ADJP(ADJP*              -    -   -   -       *            *        *         *            *        *      *            *             *       -
nw/wsj/15/wsj_1542   0   43            larger   JJR               *)             -    -   -   -       *            *        *         *            *        *      *            *             *       -
nw/wsj/15/wsj_1542   0   44              than    IN          (SBAR*              -    -   -   -       *            *        *         *            *        *      *            *             *       -
nw/wsj/15/wsj_1542   0   45                it   PRP          (S(NP*)             -    -   -   -       *            *        *         *            *        *      *            *        (ARG1*)     (2)
nw/wsj/15/wsj_1542   0   46          actually    RB          (ADVP*)             -    -   -   -       *            *        *         *            *        *      *            *    (ARGM-ADV*)      -
nw/wsj/15/wsj_1542   0   47               was   VBD   (VP*))))))))))             be  01   1   -       *            *)       *         *            *        *      *            *)          (V*)      -
nw/wsj/15/wsj_1542   0   48                 .     .              *))             -    -   -   -       *            *        *         *            *        *      *            *             *       -

nw/wsj/15/wsj_1542   0    0        American    NNP  (TOP(S(NP(NP*          -    -   -   -        (ORG*       (ARG1*   (ARG0*       (ARG0*            *    (0
nw/wsj/15/wsj_1542   0    1            Home    NNP              *          -    -   -   -            *            *        *            *            *     -
nw/wsj/15/wsj_1542   0    2        Products    NNP              *)         -    -   -   -            *)           *)       *            *            *     -
nw/wsj/15/wsj_1542   0    3               ,      ,              *          -    -   -   -            *            *        *            *            *     -
nw/wsj/15/wsj_1542   0    4           based    VBN           (VP*        base  01   3   -            *          (V*)       *            *            *     -
nw/wsj/15/wsj_1542   0    5              in     IN           (PP*          -    -   -   -            *   (ARGM-LOC*        *            *            *     -
nw/wsj/15/wsj_1542   0    6             New    NNP           (NP*          -    -   -   -        (GPE*            *        *            *            *     -
nw/wsj/15/wsj_1542   0    7            York    NNP            *)))         -    -   -   -            *)           *)       *            *            *     -
nw/wsj/15/wsj_1542   0    8               ,      ,              *)         -    -   -   -            *            *        *)           *)           *     0)
nw/wsj/15/wsj_1542   0    9          agreed    VBD           (VP*       agree  01   3   -            *            *      (V*)           *            *     -
nw/wsj/15/wsj_1542   0   10              to     TO         (S(VP*          -    -   -   -            *            *   (ARG1*            *            *     -
nw/wsj/15/wsj_1542   0   11          recall     VB           (VP*      recall  01   2   -            *            *        *          (V*)           *     -
nw/wsj/15/wsj_1542   0   12            four     CD        (NP(NP*          -    -   -   -    (CARDINAL)           *        *       (ARG1*            *    (3
nw/wsj/15/wsj_1542   0   13           other     JJ              *          -    -   -   -            *            *        *            *            *     -
nw/wsj/15/wsj_1542   0   14        products    NNS              *)    product   -   1   -            *            *        *            *            *     -
nw/wsj/15/wsj_1542   0   15               ,      ,              *          -    -   -   -            *            *        *            *            *     -
nw/wsj/15/wsj_1542   0   16       trazadone     NN           (NP*          -    -   -   -            *            *        *            *            *     -
nw/wsj/15/wsj_1542   0   17               ,      ,              *          -    -   -   -            *            *        *            *            *     -
nw/wsj/15/wsj_1542   0   18         doxepin     NN              *          -    -   -   -            *            *        *            *            *     -
nw/wsj/15/wsj_1542   0   19               ,      ,              *          -    -   -   -            *            *        *            *            *     -
nw/wsj/15/wsj_1542   0   20        diazepam     NN              *          -    -   -   -            *            *        *            *            *     -
nw/wsj/15/wsj_1542   0   21             and     CC              *          -    -   -   -            *            *        *            *            *     -
nw/wsj/15/wsj_1542   0   22       lorazapam     NN             *))         -    -   -   -            *            *        *            *)           *     3)
nw/wsj/15/wsj_1542   0   23               ,      ,              *          -    -   -   -            *            *        *            *            *     -
nw/wsj/15/wsj_1542   0   24         because     IN           (PP*          -    -   -   -            *            *        *   (ARGM-CAU*            *     -
nw/wsj/15/wsj_1542   0   25              of     IN              *          -    -   -   -            *            *        *            *            *     -
nw/wsj/15/wsj_1542   0   26        concerns    NNS        (NP(NP*)    concern   -   2   -            *            *        *            *            *     -
nw/wsj/15/wsj_1542   0   27           about     IN           (PP*          -    -   -   -            *            *        *            *            *     -
nw/wsj/15/wsj_1542   0   28            data    NNS        (NP(NP*)         -    -   -   -            *            *        *            *       (ARG1*)    -
nw/wsj/15/wsj_1542   0   29       submitted    VBN           (VP*      submit  01   2   -            *            *        *            *          (V*)    -
nw/wsj/15/wsj_1542   0   30              in     IN           (PP*          -    -   -   -            *            *        *            *   (ARGM-LOC*     -
nw/wsj/15/wsj_1542   0   31           their   PRP$           (NP*          -    -   -   -            *            *        *            *            *    (3)
nw/wsj/15/wsj_1542   0   32        original     JJ              *          -    -   -   -            *            *        *            *            *     -
nw/wsj/15/wsj_1542   0   33        approval     NN              *    approval   -   1   -            *            *        *            *            *     -
nw/wsj/15/wsj_1542   0   34    applications    NNS             *))         -    -   -   -            *            *        *            *            *)    -
nw/wsj/15/wsj_1542   0   35          before     IN           (PP*          -    -   -   -            *            *        *            *   (ARGM-LOC*     -
nw/wsj/15/wsj_1542   0   36             the     DT           (NP*          -    -   -   -            *            *        *            *            *    (4
nw/wsj/15/wsj_1542   0   37             FDA    NNP    *)))))))))))         -    -   -   -         (ORG)           *        *)           *)           *)    4)
nw/wsj/15/wsj_1542   0   38               .      .             *))         -    -   -   -            *            *        *            *            *     -

nw/wsj/15/wsj_1542   0    0          No    DT  (TOP(S(S(NP(NP*         -    -   -   -       *   (ARG1*   (ARG1*    -
nw/wsj/15/wsj_1542   0    1      safety    NN                *         -    -   -   -       *        *        *    -
nw/wsj/15/wsj_1542   0    2    problems   NNS                *)   problem   -   1   -       *        *        *    -
nw/wsj/15/wsj_1542   0    3        with    IN             (PP*         -    -   -   -       *        *        *    -
nw/wsj/15/wsj_1542   0    4         the    DT             (NP*         -    -   -   -       *        *        *   (3
nw/wsj/15/wsj_1542   0    5    products   NNS              *)))   product   -   1   -       *        *)       *    3)
nw/wsj/15/wsj_1542   0    6         are   VBP             (VP*         -    -   -   -       *        *        *    -
nw/wsj/15/wsj_1542   0    7       known   VBN           (VP*)))      know  01   -   -       *      (V*)       *)   -
nw/wsj/15/wsj_1542   0    8           ,     ,                *         -    -   -   -       *        *        *    -
nw/wsj/15/wsj_1542   0    9         the    DT             (NP*         -    -   -   -       *        *   (ARG0*   (4
nw/wsj/15/wsj_1542   0   10         FDA   NNP                *)        -    -   -   -    (ORG)       *        *)   4)
nw/wsj/15/wsj_1542   0   11        said   VBD             (VP*)       say  01   1   -       *        *      (V*)   -
nw/wsj/15/wsj_1542   0   12           .     .               *))        -    -   -   -       *        *        *    -

nw/wsj/15/wsj_1542   0    0              An    DT   (TOP(S(NP*       -    -   -   -       *   (ARG0*             *     -
nw/wsj/15/wsj_1542   0    1             FDA   NNP            *       -    -   -   -    (ORG)       *             *    (4)
nw/wsj/15/wsj_1542   0    2    spokesperson    NN            *)      -    -   -   -       *        *)            *     -
nw/wsj/15/wsj_1542   0    3            said   VBD         (VP*      say  01   1   -       *      (V*)            *     -
nw/wsj/15/wsj_1542   0    4             the    DT  (SBAR(S(NP*       -    -   -   -       *   (ARG1*        (ARG1*    (5
nw/wsj/15/wsj_1542   0    5           drugs   NNS            *)    drug   -   1   -       *        *             *)    5)
nw/wsj/15/wsj_1542   0    6             are   VBP         (VP*       be  01   1   -       *        *           (V*)    -
nw/wsj/15/wsj_1542   0    7           still    RB       (ADVP*)      -    -   -   -       *        *    (ARGM-TMP*)    -
nw/wsj/15/wsj_1542   0    8       available    JJ       (ADJP*)      -    -   -   -       *        *        (ARG2*)    -
nw/wsj/15/wsj_1542   0    9           under    IN         (PP*       -    -   -   -       *        *    (ARGM-LOC*     -
nw/wsj/15/wsj_1542   0   10           other    JJ         (NP*       -    -   -   -       *        *             *     -
nw/wsj/15/wsj_1542   0   11           brand    NN            *    brand   -   1   -       *        *             *     -
nw/wsj/15/wsj_1542   0   12           names   NNS       *))))))    name   -   1   -       *        *)            *)    -
nw/wsj/15/wsj_1542   0   13               .     .           *))      -    -   -   -       *        *             *     -

nw/wsj/15/wsj_1542   0    0            Last    JJ    (TOP(S(NP*              -    -   -   -       (DATE*   (ARGM-TMP*            *        *        *        *    (1
nw/wsj/15/wsj_1542   0    1           month    NN             *)          month   -   2   -            *)           *)           *        *        *        *     1)
nw/wsj/15/wsj_1542   0    2               ,     ,             *              -    -   -   -            *            *            *        *        *        *     -
nw/wsj/15/wsj_1542   0    3        American   NNP          (NP*              -    -   -   -        (ORG*       (ARG0*            *        *        *        *    (0
nw/wsj/15/wsj_1542   0    4            Home   NNP             *              -    -   -   -            *            *            *        *        *        *     -
nw/wsj/15/wsj_1542   0    5        Products   NNP             *)             -    -   -   -            *)           *)           *        *        *        *     0)
nw/wsj/15/wsj_1542   0    6            said   VBD          (VP*             say  01   1   -            *          (V*)           *        *        *        *     -
nw/wsj/15/wsj_1542   0    7              it   PRP   (SBAR(S(NP*)             -    -   -   -            *       (ARG1*       (ARG0*)       *        *        *    (0)
nw/wsj/15/wsj_1542   0    8             was   VBD          (VP*              -    -   -   -            *            *            *        *        *        *     -
nw/wsj/15/wsj_1542   0    9      suspending   VBG          (VP*         suspend  01   3   -            *            *          (V*)       *        *        *     -
nw/wsj/15/wsj_1542   0   10      production    NN       (NP(NP*      production  01   6   -            *            *       (ARG1*      (V*)       *        *     -
nw/wsj/15/wsj_1542   0   11             and    CC             *              -    -   -   -            *            *            *        *        *        *     -
nw/wsj/15/wsj_1542   0   12    distribution    NN             *)   distribution  01   1   -            *            *            *        *      (V*)       *     -
nw/wsj/15/wsj_1542   0   13              of    IN          (PP*              -    -   -   -            *            *            *   (ARG1*   (ARG1*        *     -
nw/wsj/15/wsj_1542   0   14             all    DT       (NP(NP*              -    -   -   -            *            *            *        *        *        *     -
nw/wsj/15/wsj_1542   0   15             21     CD             *)             -    -   -   -    (CARDINAL)           *            *        *        *        *     -
nw/wsj/15/wsj_1542   0   16              of    IN          (PP*              -    -   -   -            *            *            *        *        *        *     -
nw/wsj/15/wsj_1542   0   17         Quantum   NNP       (NP(NP*              -    -   -   -         (ORG)           *            *        *        *        *    (6
nw/wsj/15/wsj_1542   0   18              's   POS             *)             -    -   -   -            *            *            *        *        *        *     6)
nw/wsj/15/wsj_1542   0   19         generic    JJ             *              -    -   -   -            *            *            *        *        *        *     -
nw/wsj/15/wsj_1542   0   20            drug    NN             *            drug   -   1   -            *            *            *        *        *        *     -
nw/wsj/15/wsj_1542   0   21        products   NNS         *)))))        product   -   1   -            *            *            *)       *)       *)       *     -
nw/wsj/15/wsj_1542   0   22         pending   VBG          (PP*              -    -   -   -            *            *   (ARGM-TMP*        *        *        *     -
nw/wsj/15/wsj_1542   0   23             the    DT       (NP(NP*              -    -   -   -            *            *            *        *        *        *     -
nw/wsj/15/wsj_1542   0   24      completion    NN             *)     completion  01   2   -            *            *            *        *        *      (V*)    -
nw/wsj/15/wsj_1542   0   25              of    IN          (PP*              -    -   -   -            *            *            *        *        *   (ARG1*     -
nw/wsj/15/wsj_1542   0   26              an    DT          (NP*              -    -   -   -            *            *            *        *        *        *     -
nw/wsj/15/wsj_1542   0   27      exhaustive    JJ             *              -    -   -   -            *            *            *        *        *        *     -
nw/wsj/15/wsj_1542   0   28        internal    JJ             *              -    -   -   -            *            *            *        *        *        *     -
nw/wsj/15/wsj_1542   0   29           audit    NN     *)))))))))             -    -   -   -            *            *)           *)       *        *        *)    -
nw/wsj/15/wsj_1542   0   30               .     .            *))             -    -   -   -            *            *            *        *        *        *     -

nw/wsj/15/wsj_1542   0    0               It   PRP   (TOP(S(NP*)              -    -   -   -       *        (ARG0*)            *    (0)
nw/wsj/15/wsj_1542   0    1             also    RB       (ADVP*)              -    -   -   -       *    (ARGM-DIS*)            *     -
nw/wsj/15/wsj_1542   0    2      temporarily    RB       (ADVP*)              -    -   -   -       *    (ARGM-TMP*)            *     -
nw/wsj/15/wsj_1542   0    3           closed   VBD         (VP*            close  01   1   -       *           (V*)            *     -
nw/wsj/15/wsj_1542   0    4          Quantum   NNP         (NP*)              -    -   -   -    (ORG)       (ARG1*)            *    (6)
nw/wsj/15/wsj_1542   0    5                ,     ,            *               -    -   -   -       *             *             *     -
nw/wsj/15/wsj_1542   0    6          because    IN         (PP*               -    -   -   -       *    (ARGM-CAU*             *     -
nw/wsj/15/wsj_1542   0    7               of    IN            *               -    -   -   -       *             *             *     -
nw/wsj/15/wsj_1542   0    8              the    DT      (NP(NP*               -    -   -   -       *             *             *     -
nw/wsj/15/wsj_1542   0    9         internal    JJ            *               -    -   -   -       *             *             *     -
nw/wsj/15/wsj_1542   0   10    investigation    NN            *)   investigation   -   1   -       *             *             *     -
nw/wsj/15/wsj_1542   0   11                ,     ,            *               -    -   -   -       *             *             *     -
nw/wsj/15/wsj_1542   0   12               as    RB            *               -    -   -   -       *             *             *     -
nw/wsj/15/wsj_1542   0   13             well    RB            *               -    -   -   -       *             *             *     -
nw/wsj/15/wsj_1542   0   14               as    IN            *               -    -   -   -       *             *             *     -
nw/wsj/15/wsj_1542   0   15              the    DT      (NP(NP*               -    -   -   -       *             *        (ARG0*    (4
nw/wsj/15/wsj_1542   0   16              FDA   NNP            *               -    -   -   -    (ORG)            *             *     -
nw/wsj/15/wsj_1542   0   17               's   POS            *)              -    -   -   -       *             *             *)    4)
nw/wsj/15/wsj_1542   0   18          ongoing    JJ            *               -    -   -   -       *             *    (ARGM-TMP*)    -
nw/wsj/15/wsj_1542   0   19          inquiry    NN         *))))         inquiry  01   1   -       *             *)          (V*)    -
nw/wsj/15/wsj_1542   0   20                .     .           *))              -    -   -   -       *             *             *     -

nw/wsj/15/wsj_1542   0    0           In    IN    (TOP(S(PP*       -    -   -   -         *             *   (ARGM-LOC*    -
nw/wsj/15/wsj_1542   0    1          New   NNP  (NP(NML(NML*       -    -   -   -     (ORG*    (ARGM-LOC*            *    -
nw/wsj/15/wsj_1542   0    2         York   NNP             *)      -    -   -   -         *             *            *    -
nw/wsj/15/wsj_1542   0    3        Stock   NNP             *       -    -   -   -         *             *            *    -
nw/wsj/15/wsj_1542   0    4     Exchange   NNP             *)      -    -   -   -         *)            *)           *    -
nw/wsj/15/wsj_1542   0    5    composite    JJ             *       -    -   -   -         *    (ARGM-ADJ*)           *    -
nw/wsj/15/wsj_1542   0    6      trading    NN            *))   trade  01   1   -         *           (V*)           *)   -
nw/wsj/15/wsj_1542   0    7            ,     ,             *       -    -   -   -         *             *            *    -
nw/wsj/15/wsj_1542   0    8     American   NNP          (NP*       -    -   -   -     (ORG*             *       (ARG1*   (0
nw/wsj/15/wsj_1542   0    9         Home   NNP             *       -    -   -   -         *             *            *    -
nw/wsj/15/wsj_1542   0   10     Products   NNP             *)      -    -   -   -         *)            *            *)   0)
nw/wsj/15/wsj_1542   0   11         rose   VBD          (VP*     rise  01   2   -         *             *          (V*)   -
nw/wsj/15/wsj_1542   0   12          75     CD          (NP*       -    -   -   -   (MONEY*             *       (ARG2*    -
nw/wsj/15/wsj_1542   0   13        cents   NNS             *)    cent   -   1   -         *)            *            *)   -
nw/wsj/15/wsj_1542   0   14           to    IN          (PP*       -    -   -   -         *             *       (ARG4*    -
nw/wsj/15/wsj_1542   0   15            $     $          (NP*       -    -   -   -         *             *            *    -
nw/wsj/15/wsj_1542   0   16         105     CD            *))      -    -   -   -    (MONEY)            *            *)   -
nw/wsj/15/wsj_1542   0   17           on    IN          (PP*       -    -   -   -         *             *   (ARGM-TMP*    -
nw/wsj/15/wsj_1542   0   18       Friday   NNP        (NP*)))      -    -   -   -     (DATE)            *            *)   -
nw/wsj/15/wsj_1542   0   19            .     .            *))      -    -   -   -         *             *            *    -

#end document
